"Topical" HDL for vein grafts: a new solution to an old problem?
作者信息
Asmis Reto
机构信息
Departments of Clinical Laboratory Sciences and Biochemistry, University of Texas Health Science Center at San Antonio, TX, USA.
出版信息
Atherosclerosis. 2011 Feb;214(2):259-60. doi: 10.1016/j.atherosclerosis.2010.11.016. Epub 2010 Nov 23.
Abstract
摘要
相似文献
1
"Topical" HDL for vein grafts: a new solution to an old problem?用于静脉移植物的“局部”高密度脂蛋白：解决老问题的新方法？
Atherosclerosis. 2011 Feb;214(2):259-60. doi: 10.1016/j.atherosclerosis.2010.11.016. Epub 2010 Nov 23.
2
Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice.局部给予高密度脂蛋白可减少载脂蛋白 E 缺乏小鼠的静脉移植物动脉粥样硬化。
Atherosclerosis. 2011 Feb;214(2):271-8. doi: 10.1016/j.atherosclerosis.2010.09.024. Epub 2010 Sep 29.
3
In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor.电穿孔介导的非病毒组织金属蛋白酶抑制剂-1 氨基末端片段与尿激酶（TIMP-1.ATF）连接的基因转移抑制静脉移植物疾病
J Vasc Surg. 2010 Feb;51(2):429-37. doi: 10.1016/j.jvs.2009.09.026. Epub 2009 Dec 24.
4
A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease.一种新型尿激酶受体靶向抑制剂可抑制纤溶酶和基质金属蛋白酶，从而抑制静脉移植物疾病。
Cardiovasc Res. 2010 Nov 1;88(2):367-75. doi: 10.1093/cvr/cvq203. Epub 2010 Jun 17.
5
C1-esterase inhibitor protects against early vein graft remodeling under arterial blood pressure.C1 酯酶抑制剂可预防动脉血压下早期静脉移植物重塑。
Atherosclerosis. 2012 Jan;220(1):86-92. doi: 10.1016/j.atherosclerosis.2011.10.021. Epub 2011 Oct 25.
6
Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice.膜联蛋白 A5 治疗可减轻血管炎症和重构，改善小鼠的内皮功能。
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):95-101. doi: 10.1161/ATVBAHA.110.216747. Epub 2010 Oct 14.
7
Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.局部应用阿司匹林通过内皮保护作用抑制静脉移植物中的血栓形成和新生内膜形成。
Circ Res. 2004 Jun 11;94(11):1466-73. doi: 10.1161/01.RES.0000129570.06647.00. Epub 2004 Apr 29.
8
Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice.Toll 样受体 4 参与人及小鼠静脉移植物重塑，局部基因沉默可降低高脂血症 APOE*3Leiden 小鼠的静脉移植物疾病。
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1033-40. doi: 10.1161/ATVBAHA.111.223271. Epub 2011 Feb 17.
9
Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice.基质金属蛋白酶-9基因敲除对小鼠静脉移植物重塑的影响。
J Vasc Res. 2010;47(4):299-308. doi: 10.1159/000265564. Epub 2009 Dec 16.
10
CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis.内皮型四氢生物蝶呤通过CCR2介导的抗炎作用抑制血管损伤诱导的动脉粥样硬化加速。
Circulation. 2008 Sep 30;118(14 Suppl):S71-7. doi: 10.1161/CIRCULATIONAHA.107.753558.
本文引用的文献
1
Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice.局部给予高密度脂蛋白可减少载脂蛋白 E 缺乏小鼠的静脉移植物动脉粥样硬化。
Atherosclerosis. 2011 Feb;214(2):271-8. doi: 10.1016/j.atherosclerosis.2010.09.024. Epub 2010 Sep 29.
2
Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis.循环内皮祖细胞不会促进小鼠动脉粥样硬化斑块中的内皮细胞。
Circulation. 2010 Feb 23;121(7):898-905. doi: 10.1161/CIRCULATIONAHA.109.885459. Epub 2010 Feb 8.
3
Coronary vein graft disease: pathogenesis and prevention.冠状动脉移植血管疾病：发病机制与预防
Can J Cardiol. 2009 Feb;25(2):e57-62. doi: 10.1016/s0828-282x(09)70486-6.
4
Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.早期隐静脉移植失败与冠状动脉搭桥手术后结局的关系。
Am J Cardiol. 2005 Nov 1;96(9):1254-9. doi: 10.1016/j.amjcard.2005.06.067. Epub 2005 Sep 6.
5
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).美国心脏病学会/美国心脏协会冠状动脉搭桥手术2004年指南更新：美国心脏病学会/美国心脏协会实践指南工作组（更新1999年冠状动脉搭桥手术指南委员会）报告
Circulation. 2004 Oct 5;110(14):e340-437.
6
Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood.利用人外周血和脐带血鉴定内皮祖细胞的新型层级结构。
Blood. 2004 Nov 1;104(9):2752-60. doi: 10.1182/blood-2004-04-1396. Epub 2004 Jun 29.
7
Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later.
Am J Cardiol. 1984 Jun 15;53(12):102C-107C. doi: 10.1016/0002-9149(84)90759-8.
8
Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences.
Circulation. 1985 Dec;72(6 Pt 2):V71-8.
9
Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts.乳内动脉和大隐静脉冠状动脉搭桥术的长期（5至12年）系列研究。
J Thorac Cardiovasc Surg. 1985 Feb;89(2):248-58.
10
Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.冠状动脉搭桥术后1年隐静脉移植物通畅情况及抗血小板治疗的效果。退伍军人管理局合作研究的结果
Circulation. 1989 Nov;80(5):1190-7. doi: 10.1161/01.cir.80.5.1190.
Zotero 插件